Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds?

Page 1 of 2

Should Pacira Pharmaceuticals Inc (NASDAQ:PCRX) investors track the following data?

To the average investor, there are many methods market participants can use to analyze publicly traded companies. Some of the most under-the-radar are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top money managers can beat the market by a healthy margin (see just how much).

Just as necessary, optimistic insider trading sentiment is another way to look at the investments you’re interested in. There are lots of incentives for a bullish insider to cut shares of his or her company, but just one, very simple reason why they would behave bullishly. Many empirical studies have demonstrated the useful potential of this method if piggybackers understand where to look (learn more here).

Furthermore, we’re going to examine the latest info surrounding Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

What does the smart money think about Pacira Pharmaceuticals Inc (NASDAQ:PCRX)?

Heading into Q3, a total of 12 of the hedge funds we track were bullish in this stock, a change of 20% from the previous quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were boosting their stakes substantially.

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)When using filings from the hedgies we track, Jacob Gottlieb’s Visium Asset Management had the largest position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX), worth close to $58.3 million, accounting for 1.4% of its total 13F portfolio. Coming in second is Millennium Management, managed by Israel Englander, which held a $16.8 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other hedge funds that hold long positions include Samuel Isaly’s OrbiMed Advisors, Daniel Arbess’s Xerion and Brian Ashford-Russell and Tim Woolley’s Polar Capital.

As aggregate interest spiked, certain bigger names were breaking ground themselves. Visium Asset Management, managed by Jacob Gottlieb, created the most outsized position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Visium Asset Management had 58.3 million invested in the company at the end of the quarter. Kevin C. Tang’s Tang Capital Management also initiated a $25.8 million position during the quarter. The other funds with brand new PCRX positions are Israel Englander’s Millennium Management, Samuel Isaly’s OrbiMed Advisors, and Daniel Arbess’s Xerion.

What do corporate executives and insiders think about Pacira Pharmaceuticals Inc (NASDAQ:PCRX)?

Insider buying is particularly usable when the company we’re looking at has seen transactions within the past six months. Over the last half-year time frame, Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll check out the relationship between both of these indicators in other stocks similar to Pacira Pharmaceuticals Inc (NASDAQ:PCRX). These stocks are Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), and Impax Laboratories Inc (NASDAQ:IPXL). This group of stocks belong to the drug manufacturers – major industry and their market caps are closest to PCRX’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!